ATE525082T1 - Compstatin-analoga mit verbesserter wirkung - Google Patents

Compstatin-analoga mit verbesserter wirkung

Info

Publication number
ATE525082T1
ATE525082T1 AT03759343T AT03759343T ATE525082T1 AT E525082 T1 ATE525082 T1 AT E525082T1 AT 03759343 T AT03759343 T AT 03759343T AT 03759343 T AT03759343 T AT 03759343T AT E525082 T1 ATE525082 T1 AT E525082T1
Authority
AT
Austria
Prior art keywords
compounds
improved effects
peptides
disclosed
compstatin analogues
Prior art date
Application number
AT03759343T
Other languages
English (en)
Inventor
John Lambris
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Application granted granted Critical
Publication of ATE525082T1 publication Critical patent/ATE525082T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
AT03759343T 2002-09-20 2003-09-22 Compstatin-analoga mit verbesserter wirkung ATE525082T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41222002P 2002-09-20 2002-09-20
PCT/US2003/029653 WO2004026328A1 (en) 2002-09-20 2003-09-22 Compstatin analogs with improved activity

Publications (1)

Publication Number Publication Date
ATE525082T1 true ATE525082T1 (de) 2011-10-15

Family

ID=32030834

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03759343T ATE525082T1 (de) 2002-09-20 2003-09-22 Compstatin-analoga mit verbesserter wirkung

Country Status (13)

Country Link
US (4) US7989589B2 (de)
EP (3) EP2311479B1 (de)
JP (3) JP4614222B2 (de)
AT (1) ATE525082T1 (de)
AU (1) AU2003275075A1 (de)
CA (2) CA2502690C (de)
CY (1) CY1112198T1 (de)
DK (1) DK1549333T3 (de)
ES (1) ES2373649T3 (de)
HK (2) HK1156860A1 (de)
PT (1) PT1549333E (de)
SI (1) SI1549333T1 (de)
WO (1) WO2004026328A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1549333T1 (sl) * 2002-09-20 2012-02-29 Univ Pennsylvania Analogi kompstatina z izboljĺ ano aktivnostjo
WO2005118020A1 (en) * 2004-04-21 2005-12-15 Allvivo, Inc. Surface coating comprising bioactive compound
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
BRPI0617186A2 (pt) 2005-10-08 2011-07-19 Potentia Pharmaceuticals Inc uso de análogo de compstatina, implante ocular, micropartìcula ou nanopartìcula, composição, composto multivalente, ácido nucléico, vetor de expressão, célula hospedeira recombinante, proteìna de fusão e método de produção e teste
AU2013200981B2 (en) * 2005-11-28 2016-01-14 The Trustees Of The University Of Pennsylvania Potent compstatin analogs
PT1960422E (pt) * 2005-11-28 2012-08-16 Univ Pennsylvania Análogos de compstatina potentes
EP2979729A3 (de) 2007-02-05 2016-05-11 Apellis Pharmaceuticals, Inc. Compstatin analoga zur behandlung von entzundungserkrankungen der atemwege
US8442776B2 (en) 2007-06-08 2013-05-14 The Trustees Of The University Of Pennsylvania Structure of compstatin-C3 complex and use for rational drug design
US8563259B2 (en) 2007-06-29 2013-10-22 The Trustees Of The University Of Pennsylvania Complement-mediated thrombophilic assay
US20110092446A1 (en) * 2007-07-20 2011-04-21 Cedric Francois Compositions and methods for treatment of trauma
CN101854916A (zh) * 2007-10-02 2010-10-06 博泰迪亚制药公司 由凝胶持续递送坎普他汀类似物
CA2718588A1 (en) 2008-02-19 2009-08-27 The Trustees Of The University Of Pennsylvania Complement inhibitors as therapeutic agents for treatment of cancer
US20110190221A1 (en) * 2008-03-28 2011-08-04 Apellis Ag Modulation and repletion/enhancement of the complement system for treatment of trauma
WO2010022149A1 (en) 2008-08-20 2010-02-25 The Trustees Of The University Of Pennsylvania Complement inhibitors for treatment of injury form intracerebral hemorrhage
WO2010039690A1 (en) 2008-09-30 2010-04-08 The Trustees Of The University Of Pennsylvania Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors
HUE035378T2 (en) * 2009-05-01 2018-05-02 Univ Pennsylvania Compstatin with peptide framework and C-terminal modifications
US9291622B2 (en) 2009-05-21 2016-03-22 Apellis Pharmaceuticals, Inc. Complement assays and uses thereof
US20110104154A1 (en) 2009-10-30 2011-05-05 Alcon Research, Ltd. Single nucleotide polymorphisms and genes associated with age-related macular degeneration
US9358266B2 (en) 2010-02-25 2016-06-07 The Trustees Of The University Of Pennsylvania Treatment of sepsis using complement inhibitors
WO2011163394A2 (en) 2010-06-22 2011-12-29 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
CA2813049A1 (en) 2010-09-23 2012-03-29 The Trustees Of The University Of Pennsylvania Modified compstatin with improved stability and binding properties
WO2012095519A1 (en) 2011-01-13 2012-07-19 Leibniz-Institut Für Naturstoff-Forschung Und Infektionsbiologie Potent inhibitors of complement activation
US20140219999A1 (en) 2011-04-01 2014-08-07 The Trustees Of The University Of Pennsylvania Treatment of colon cancer using complement inhibitors
JP6522337B2 (ja) * 2011-05-11 2019-05-29 アペリス・ファーマシューティカルズ・インコーポレイテッドＡｐｅｌｌｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 細胞反応性、長時間作用型または標的化コンプスタチン類似体およびその使用
WO2012162215A1 (en) 2011-05-20 2012-11-29 The Trustees Of The University Of Pennsylvania Promotion of fracture healing using complement inhibitors
WO2012174055A1 (en) 2011-06-13 2012-12-20 The Trustees Of The University Of Pennsylvania Wound healing using complement inhibitors
CN103796667A (zh) 2011-06-22 2014-05-14 艾普莱斯制药公司 用补体抑制剂治疗慢性障碍的方法
JP6249949B2 (ja) * 2011-09-07 2017-12-20 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 薬物動態特性の改善されたコンプスタチンアナログ
WO2014078734A2 (en) * 2012-11-15 2014-05-22 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
CA2891673A1 (en) 2012-11-15 2014-05-22 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
IL282401B (en) 2013-12-12 2022-08-01 Alnylam Pharmaceuticals Inc Complementary component irna compositions and methods for using them
US10238700B2 (en) 2014-01-02 2019-03-26 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
WO2015142701A1 (en) 2014-03-17 2015-09-24 The Trustees Of The University Of Pennsylvania Compstatin analogs with improved potency and pharmacokinetic properties
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
CN117503905A (zh) 2015-10-07 2024-02-06 阿佩利斯制药有限公司 给药方案
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
AU2018227849B2 (en) 2017-03-01 2022-04-28 Achillion Pharmaceuticals, Inc. Aryl, heteroary, and heterocyclic pharmaceutical compounds for treatment of medical disorders
CA3059304A1 (en) 2017-04-07 2018-10-11 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
US11866701B2 (en) 2017-11-01 2024-01-09 Alnylam Pharmaceuticals, Inc. Complement component C3 iRNA compositions and methods of use thereof
KR20200135797A (ko) 2018-02-27 2020-12-03 제트피 에스피브이 3 케이/에스 콤프스타틴 유사체 및 이들의 의학적 용도
US11884747B2 (en) 2018-04-06 2024-01-30 The Trustees Of The University Of Pennsylvania Compstatin analogs with increased solubility and improved pharmacokinetic properties
WO2020051532A2 (en) 2018-09-06 2020-03-12 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
KR20210057086A (ko) 2018-09-06 2021-05-20 아칠리온 파르마세우티칼스 인코포레이티드 다니코판의 형태체 형태
CN112996497A (zh) 2018-09-25 2021-06-18 艾其林医药公司 补体因子d抑制剂的形态形式
KR20220066287A (ko) 2019-08-27 2022-05-24 제트피 에스피브이 3 케이/에스 콤프스타틴 유사체 및 이의 의약 용도
WO2021081026A1 (en) 2019-10-22 2021-04-29 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof
WO2021178607A1 (en) 2020-03-05 2021-09-10 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases
IL297680A (en) 2020-04-30 2022-12-01 Alnylam Pharmaceuticals Inc IRNA compounds complement factor b (cfb) and methods of using them
EP4149473A1 (de) 2020-05-12 2023-03-22 Alexion Pharmaceuticals, Inc. Verwendung von komplementfaktor-d-hemmern allein oder in kombination mit anti-c5-antikörpern zur behandlung von paroxysmaler nächtlicher hämoglobinurie
CN116209671A (zh) 2020-07-16 2023-06-02 西兰制药第三特殊目的公司 补体因子c3的抑制剂及其医学用途
WO2022150260A1 (en) 2021-01-05 2022-07-14 Alnylam Pharmaceuticals, Inc. COMPLEMENT COMPONENT 9 (C9) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
WO2023044370A2 (en) 2021-09-17 2023-03-23 Alnylam Pharmaceuticals, Inc. Irna compositions and methods for silencing complement component 3 (c3)
WO2023076451A1 (en) 2021-10-29 2023-05-04 Alnylam Pharmaceuticals, Inc. Complement factor b (cfb) irna compositions and methods of use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2295746A1 (fr) 1974-12-23 1976-07-23 Francaise Coop Pharma Nouveaux derives du tryptophane a activite nerveuse centrale renforcee
IT1179866B (it) 1984-12-12 1987-09-16 Rotta Research Lab Derivati del triptofano farmaceuticamente attivi e composizioni farmaceutiche che li contengono
US4576750A (en) * 1985-04-22 1986-03-18 Merck & Co., Inc. Tryptophan derivative
US4807097A (en) * 1986-05-14 1989-02-21 Gammache Richard J Miniature flashlight
US5256642A (en) * 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
US5167960A (en) * 1988-08-03 1992-12-01 New England Deaconess Hospital Corporation Hirudin-coated biocompatible substance
AU7749491A (en) 1990-04-23 1991-11-11 Rijksuniversiteit Te Utrecht Cyclic peptides and their use
ES2204944T3 (es) 1994-03-03 2004-05-01 Alexion Pharmaceuticals, Inc. Genes y proteinas de fusion inhibidores del complemento terminal.
US5776970A (en) 1994-04-28 1998-07-07 Yeda Research And Development Co. Ltd. Tryptophan derivatives as protein tyrosine kinase blockers and their use in the treatment of neoplastic diseases
US6319897B1 (en) * 1996-03-13 2001-11-20 John D. Lambris Peptides which inhibit complement activation
US6221621B1 (en) * 1997-03-06 2001-04-24 Bard Diagnostic Sciences, Inc. Methods of screening for colorectal cancers in which a complement Factor I or related protein is associated
US6169057B1 (en) * 1997-09-04 2001-01-02 The Regents Of The University Of California Use of tryptophan and analogs as plant growth regulators
WO1999013899A1 (en) * 1997-09-17 1999-03-25 Trustees Of The University Of Pennsylvania Peptides and peptidomimetics for inhibiting complement activation
WO1999052539A1 (en) * 1998-04-10 1999-10-21 Mayo Foundation For Medical Education And Research Neo-tryptophan
SI1549333T1 (sl) * 2002-09-20 2012-02-29 Univ Pennsylvania Analogi kompstatina z izboljĺ ano aktivnostjo
PT1960422E (pt) * 2005-11-28 2012-08-16 Univ Pennsylvania Análogos de compstatina potentes

Also Published As

Publication number Publication date
US20180118785A1 (en) 2018-05-03
US20170190741A9 (en) 2017-07-06
ES2373649T3 (es) 2012-02-07
JP2010280688A (ja) 2010-12-16
EP2311479A1 (de) 2011-04-20
CA2502690A1 (en) 2004-04-01
DK1549333T3 (da) 2012-01-16
US20150158913A1 (en) 2015-06-11
JP2013138673A (ja) 2013-07-18
JP5860573B2 (ja) 2016-02-16
HK1156860A1 (en) 2012-06-22
US8883413B2 (en) 2014-11-11
EP1549333B1 (de) 2011-09-21
JP2006505254A (ja) 2006-02-16
CY1112198T1 (el) 2015-12-09
HK1156862A1 (en) 2012-06-22
CA2502690C (en) 2014-01-28
WO2004026328A1 (en) 2004-04-01
US7989589B2 (en) 2011-08-02
AU2003275075A1 (en) 2004-04-08
CA2833202C (en) 2017-08-01
PT1549333E (pt) 2012-01-03
EP2311479B1 (de) 2014-07-23
JP4614222B2 (ja) 2011-01-19
EP1549333A1 (de) 2005-07-06
EP1549333A4 (de) 2008-05-28
EP2311480B1 (de) 2013-06-26
US20100222550A1 (en) 2010-09-02
EP2311480A1 (de) 2011-04-20
SI1549333T1 (sl) 2012-02-29
CA2833202A1 (en) 2004-04-01
US20110275150A1 (en) 2011-11-10

Similar Documents

Publication Publication Date Title
ATE525082T1 (de) Compstatin-analoga mit verbesserter wirkung
WO2007062249A3 (en) Potent compstatin analogs
WO2004078777A3 (en) Dipeptidyl-peptidase protected proteins
DK1329458T3 (da) Peptider som sænker blodglucoseniveauer
ATE368688T1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
MXPA03002218A (es) Peptidos antimicrobianos y metodos de uso.
CY1112875T1 (el) Sfrp και πεπτιδικα μοτιβα που διαντιδρουν με την sfrp και μεθοδοι χρησης τους
ATE278710T1 (de) Antimikrobiell wirksame peptide
ATE443076T1 (de) Von protease typ ii spaltbares peptid
ATE362487T1 (de) N-substituierte l-aminosäuren enthaltende peptide,zur prävention der beta-strang assoziation
FI20050753A (fi) Uudet peptidit
BR9711540A (pt) Inibidores de protease proteìnico estabilizados e variantes dos mesmos
ATE336501T1 (de) Chi-conotoxinpeptide als inhibitoren neuronaler amintransporter
ATE445634T1 (de) Antimikrobielle peptide
ATE419271T1 (de) Antimikrobielle peptide
ATE375360T1 (de) Peptide mit inhibierender aktivität zur produktion von stickstoffmonoxid
DE50013400D1 (de) Dna-sequenz und rekombinante herstellung eines graminaen-allergens
DE60008749D1 (de) Therapeutische peptide aus untersequenzen von bpi
SE0101519D0 (sv) Nucleic ACID
FI20040655A (fi) Proteiini- ja peptidistabilointi
DE50310131D1 (de) Peptide mit hohem cysteingehalt
WO2004078776A3 (en) Ny-eso-1 peptides which bind to class ii molecules and uses thereof
WO2001081412A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding the same, and uses thereof
EA200500624A1 (ru) Промотор для il-18bp, его получение и применение
WO2002022678A3 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1549333

Country of ref document: EP